Cargando…

Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors

BACKGROUND: The optimal treatment for adrenal metastases from hepatocellular carcinoma (HCC) has not been established. This study analyzed the effects of radiation therapy (RT) for such metastases and identified clinical features and predictors of survival in these patients. METHODS: We retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Le-Yuan, Zeng, Zhao-Chong, Fan, Jia, Chen, Bing, Rao, Sheng-xiang, He, Jian, Yang, Ping, Hou, Jia-zhou, Wu, Zhi-feng, Zhang, Jian-ying, Hu, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289365/
https://www.ncbi.nlm.nih.gov/pubmed/25421498
http://dx.doi.org/10.1186/1471-2407-14-878
_version_ 1782352103293845504
author Zhou, Le-Yuan
Zeng, Zhao-Chong
Fan, Jia
Chen, Bing
Rao, Sheng-xiang
He, Jian
Yang, Ping
Hou, Jia-zhou
Wu, Zhi-feng
Zhang, Jian-ying
Hu, Yong
author_facet Zhou, Le-Yuan
Zeng, Zhao-Chong
Fan, Jia
Chen, Bing
Rao, Sheng-xiang
He, Jian
Yang, Ping
Hou, Jia-zhou
Wu, Zhi-feng
Zhang, Jian-ying
Hu, Yong
author_sort Zhou, Le-Yuan
collection PubMed
description BACKGROUND: The optimal treatment for adrenal metastases from hepatocellular carcinoma (HCC) has not been established. This study analyzed the effects of radiation therapy (RT) for such metastases and identified clinical features and predictors of survival in these patients. METHODS: We retrospectively investigated 55 patients with adrenal metastasis from HCC who had been treated with RT. Radiation doses to the adrenal lesions ranged from 26 to 60 Gy, while the intrahepatic lesions were treated by surgical resection, transarterial chemoembolization (TACE), liver transplantation, and/or RT. RT was conducted to adrenal lesions after their intrahepatic lesions were controlled more than 2 months. The parameters studied included survival rates and tumor responses to RT. The Kaplan-Meier method was used to evaluate survival rate and the Cox regression model was used to identify potential predictors of outcome. RESULTS: The patients treated by RT had adrenal metastasis on the right side (41), the left (6), or on both sides (8). In all 55 patients, the median survival duration was 13.6 months and there was 100% pain relief after completion of RT. Adverse effects were mild to moderate. Unfavorable pretreatment predictors determined by univariate analysis were associated with multiple intrahepatic foci, metastases to additional organs, high γ-glutamyltransferase and alpha-fetoprotein levels, liver function of Child-Pugh classification B and uncontrolled primary HCC. By multivariate analysis, unfavorable predictors were multiple intrahepatic foci, metastases to additional organs and uncontrolled primary HCC. CONCLUSIONS: Radiotherapy as treatment for adrenal metastases in HCC is a good palliative therapy that is associated with reasonable safety. It appears reasonable that such patients should be considered to be treated with radiotherapy. Multiple intrahepatic foci, metastases to additional organs and uncontrolled primary HCC were unfavorable predictors.
format Online
Article
Text
id pubmed-4289365
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42893652015-01-11 Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors Zhou, Le-Yuan Zeng, Zhao-Chong Fan, Jia Chen, Bing Rao, Sheng-xiang He, Jian Yang, Ping Hou, Jia-zhou Wu, Zhi-feng Zhang, Jian-ying Hu, Yong BMC Cancer Research Article BACKGROUND: The optimal treatment for adrenal metastases from hepatocellular carcinoma (HCC) has not been established. This study analyzed the effects of radiation therapy (RT) for such metastases and identified clinical features and predictors of survival in these patients. METHODS: We retrospectively investigated 55 patients with adrenal metastasis from HCC who had been treated with RT. Radiation doses to the adrenal lesions ranged from 26 to 60 Gy, while the intrahepatic lesions were treated by surgical resection, transarterial chemoembolization (TACE), liver transplantation, and/or RT. RT was conducted to adrenal lesions after their intrahepatic lesions were controlled more than 2 months. The parameters studied included survival rates and tumor responses to RT. The Kaplan-Meier method was used to evaluate survival rate and the Cox regression model was used to identify potential predictors of outcome. RESULTS: The patients treated by RT had adrenal metastasis on the right side (41), the left (6), or on both sides (8). In all 55 patients, the median survival duration was 13.6 months and there was 100% pain relief after completion of RT. Adverse effects were mild to moderate. Unfavorable pretreatment predictors determined by univariate analysis were associated with multiple intrahepatic foci, metastases to additional organs, high γ-glutamyltransferase and alpha-fetoprotein levels, liver function of Child-Pugh classification B and uncontrolled primary HCC. By multivariate analysis, unfavorable predictors were multiple intrahepatic foci, metastases to additional organs and uncontrolled primary HCC. CONCLUSIONS: Radiotherapy as treatment for adrenal metastases in HCC is a good palliative therapy that is associated with reasonable safety. It appears reasonable that such patients should be considered to be treated with radiotherapy. Multiple intrahepatic foci, metastases to additional organs and uncontrolled primary HCC were unfavorable predictors. BioMed Central 2014-11-25 /pmc/articles/PMC4289365/ /pubmed/25421498 http://dx.doi.org/10.1186/1471-2407-14-878 Text en © Zhou et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Zhou, Le-Yuan
Zeng, Zhao-Chong
Fan, Jia
Chen, Bing
Rao, Sheng-xiang
He, Jian
Yang, Ping
Hou, Jia-zhou
Wu, Zhi-feng
Zhang, Jian-ying
Hu, Yong
Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors
title Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors
title_full Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors
title_fullStr Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors
title_full_unstemmed Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors
title_short Radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors
title_sort radiotherapy treatment of adrenal gland metastases from hepatocellular carcinoma: clinical features and prognostic factors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289365/
https://www.ncbi.nlm.nih.gov/pubmed/25421498
http://dx.doi.org/10.1186/1471-2407-14-878
work_keys_str_mv AT zhouleyuan radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors
AT zengzhaochong radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors
AT fanjia radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors
AT chenbing radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors
AT raoshengxiang radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors
AT hejian radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors
AT yangping radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors
AT houjiazhou radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors
AT wuzhifeng radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors
AT zhangjianying radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors
AT huyong radiotherapytreatmentofadrenalglandmetastasesfromhepatocellularcarcinomaclinicalfeaturesandprognosticfactors